{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:58:06Z","timestamp":1790434686644,"version":"4.1.0"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000078","name":"National Science Foundation Division of Materials Research","doi-asserted-by":"publisher","award":["DMR 21-43673 CAR"],"award-info":[{"award-number":["DMR 21-43673 CAR"]}],"id":[{"id":"10.13039\/100000078","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA270872"],"award-info":[{"award-number":["R21CA270872"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA274738"],"award-info":[{"award-number":["R01CA274738"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32EB019944"],"award-info":[{"award-number":["T32EB019944"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018776","name":"Cancer Center, University of Florida Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018776","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000070","name":"National Institute of Biomedical Imaging and Bioengineering","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000070","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006064","name":"Sontag Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006064","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005302","name":"University of Illinois at Urbana-Champaign","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005302","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.actbio.2025.08.005","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T03:42:43Z","timestamp":1754451763000},"page":"234-245","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Macroporous hydrogel-based mRNA cancer vaccine for in situ recruitment and modulation of dendritic cells"],"prefix":"10.1016","volume":"204","author":[{"given":"Jiadiao","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rimsha","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-0661","authenticated-orcid":false,"given":"Joonsu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhyanesh","family":"Baskaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savindi","family":"Devmal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1157-8786","authenticated-orcid":false,"given":"Hua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.actbio.2025.08.005_bib0001","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/nature10673","article-title":"Cancer immunotherapy comes of age","volume":"480","author":"Mellman","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2025.08.005_bib0002","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/nrd3500","article-title":"Cancer immunotherapy\u2013revisited","volume":"10","author":"Lesterhuis","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2025.08.005_bib0003","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","article-title":"Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges","volume":"15","author":"Fukumura","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/nrclinonc.2017.149","article-title":"Immunotherapy: cancer vaccines on the move","volume":"15","author":"Banchereau","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0005","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrd.2016.201","article-title":"The cancer vaccine resurgence","volume":"15","author":"Mullard","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2025.08.005_bib0006","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/B978-0-12-407190-2.00007-1","article-title":"Therapeutic cancer vaccines: past, present, and future","volume":"119","author":"Guo","year":"2013","journal-title":"Adv. Cancer Res."},{"key":"10.1016\/j.actbio.2025.08.005_bib0007","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.actbio.2025.08.005_bib0008","doi-asserted-by":"crossref","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","article-title":"PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine","volume":"17","author":"Cheever","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.actbio.2025.08.005_bib0009","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1200\/JCO.2005.04.5252","article-title":"Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer","volume":"24","author":"Small","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0010","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2025.08.005_bib0011","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1080\/08830180600992472","article-title":"Overview of tumor cell\u2013based vaccines","volume":"25","author":"Copier","year":"2006","journal-title":"Int. Rev. Immunol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0012","doi-asserted-by":"crossref","DOI":"10.1038\/natrevmats.2015.8","article-title":"Materializing the future of vaccines and immunotherapy","volume":"1","author":"Irvine","year":"2016","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0013","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1038\/nmat3775","article-title":"Engineering synthetic vaccines using cues from natural immunity","volume":"12","author":"Irvine","year":"2013","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0014","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/s41563-018-0147-9","article-title":"Biomaterial-assisted targeted modulation of immune cells in cancer treatment","volume":"17","author":"Wang","year":"2018","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2025.08.005_bib0016","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0017","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.actbio.2025.08.005_bib0018","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials of mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0019","doi-asserted-by":"crossref","first-page":"16982","DOI":"10.1021\/acsnano.1c04996","article-title":"Lipid nanoparticles- from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement","volume":"15","author":"Tenchov","year":"2021","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2025.08.005_bib0020","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0021","article-title":"Lipid nanoparticle-mediated lymph node\u2013targeting delivery of mRNA cancer vaccine elicits robust CD8+ T cell response","volume":"119","author":"Chen","year":"2022","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.actbio.2025.08.005_bib0022","first-page":"1","article-title":"Targeting cancer with mRNA\u2013lipid nanoparticles: key considerations and future prospects","author":"Kon","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0023","article-title":"Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy","author":"Zong","year":"2023","journal-title":"Adv. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0024","first-page":"1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0025","doi-asserted-by":"crossref","first-page":"eadn9961","DOI":"10.1126\/sciadv.adn9961","article-title":"Lipopolyplex-formulated mRNA cancer vaccine elicits strong neoantigen-specific T cell responses and antitumor activity","volume":"10","author":"Fan","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.actbio.2025.08.005_bib0026","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1021\/acs.nanolett.6b03329","article-title":"Lipid nanoparticle assisted mRNA delivery for potent cancer immunotherapy","volume":"17","author":"Oberli","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/j.actbio.2025.08.005_bib0027","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1038\/d41591-023-00072-0","article-title":"Personalized anti-cancer vaccine combining mRNA and immunotherapy tested in melanoma trial","volume":"29","author":"Carvalho","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2025.08.005_bib0028","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jconrel.2023.11.008","article-title":"Simultaneous dendritic cells targeting and effective endosomal escape enhance sialic acid-modified mRNA vaccine efficacy and reduce side effects","volume":"364","author":"Tang","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.actbio.2025.08.005_bib0029","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1038\/s41571-024-00902-1","article-title":"Cancer mRNA vaccines: clinical advances and future opportunities","volume":"21","author":"Sayour","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0030","doi-asserted-by":"crossref","first-page":"19550","DOI":"10.1021\/acsnano.3c05635","article-title":"mRNA cancer vaccines: construction and boosting strategies","volume":"17","author":"Liu","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.actbio.2025.08.005_bib0031","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/794528","article-title":"RNA-based vaccines in cancer immunotherapy","volume":"2015","author":"McNamara","year":"2015","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.actbio.2025.08.005_bib0032","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1038\/s41591-021-01542-z","article-title":"Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors","volume":"27","author":"Shroff","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2025.08.005_bib0033","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/s41568-023-00586-2","article-title":"mRNA-based cancer therapeutics","volume":"23","author":"Liu","year":"2023","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.actbio.2025.08.005_bib0034","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1038\/s41591-022-01937-6","article-title":"Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results","volume":"28","author":"Palmer","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.actbio.2025.08.005_bib0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nmat2357","article-title":"Infection-mimicking materials to program dendritic cells in situ","volume":"8","author":"Ali","year":"2009","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0036","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.3000359","article-title":"In situ regulation of DC subsets and T cells mediates tumor regression in mice","volume":"1","author":"Ali","year":"2009","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.actbio.2025.08.005_bib0037","doi-asserted-by":"crossref","first-page":"7556","DOI":"10.1038\/ncomms8556","article-title":"Injectable cryogel-based whole-cell cancer vaccines","volume":"6","author":"Bencherif","year":"2015","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2025.08.005_bib0038","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1038\/nbt.3071","article-title":"Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and increase vaccine efficacy","volume":"33","author":"Kim","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0039","article-title":"A facile approach to enhance antigen response for personalized cancer vaccination","author":"Li","year":"2018","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0040","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1038\/s41563-020-0680-1","article-title":"Metabolic labeling and targeted modulation of dendritic cells","volume":"19","author":"Wang","year":"2020","journal-title":"Nat. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0041","doi-asserted-by":"crossref","first-page":"5696","DOI":"10.1038\/s41467-020-19540-z","article-title":"Biomaterial-based scaffold for in situ chemo-immunotherapy to treat poorly immunogenic tumors","volume":"11","author":"Wang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.actbio.2025.08.005_bib0042","doi-asserted-by":"crossref","DOI":"10.1002\/adhm.201600773","article-title":"Multicomponent injectable hydrogels for antigen-specific tolerogenic immune modulation","volume":"6","author":"Verbeke","year":"2017","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0043","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1002\/adhm.201500618","article-title":"Injectable, pore-forming hydrogels for in vivo enrichment of immature dendritic cells","volume":"4","author":"Verbeke","year":"2015","journal-title":"Adv. Healthc. Mater."},{"key":"10.1016\/j.actbio.2025.08.005_bib0044","doi-asserted-by":"crossref","first-page":"309","DOI":"10.4049\/jimmunol.180.1.309","article-title":"Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals","volume":"180","author":"Kreiter","year":"2008","journal-title":"J. Immunol."},{"issue":"9","key":"10.1016\/j.actbio.2025.08.005_bib0045","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.3390\/ph16091270","article-title":"Tolerogenic lipid nanoparticles for delivering self-antigen mRNA for the treatment of experimental autoimmune encephalomyelitis","volume":"16","author":"Gomi","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.actbio.2025.08.005_bib0046","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.actbio.2025.08.005_bib0047","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.colsurfb.2008.09.017","article-title":"Comparison of different commercially available cationic liposome\u2013DNA lipoplexes: parameters influencing toxicity and transfection efficiency","volume":"68","author":"Masotti","year":"2009","journal-title":"Colloids Surf. B: Biointerf."},{"key":"10.1016\/j.actbio.2025.08.005_bib0048","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.addr.2004.12.004","article-title":"Implications of pharmacokinetic behavior of lipoplex for its inflammatory toxicity","volume":"57","author":"Zhang","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.actbio.2025.08.005_bib0049","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.ejps.2010.03.019","article-title":"Gene delivery by lipoplexes and polyplexes","volume":"40","author":"de Ilarduya","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.actbio.2025.08.005_bib0050","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2217\/imt.09.70","article-title":"Toll-like receptor agonists in cancer therapy","volume":"1","author":"Adams","year":"2009","journal-title":"Immunotherapy"},{"key":"10.1016\/j.actbio.2025.08.005_bib0051","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.4049\/jimmunol.174.3.1259","article-title":"Synthetic TLR agonists reveal functional differences between human TLR7 and TLR8","volume":"174","author":"Gorden","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.actbio.2025.08.005_bib0052","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1038\/nm1589","article-title":"Therapeutic targeting of innate immunity with toll-like receptor agonists and antagonists","volume":"13","author":"Kanzler","year":"2007","journal-title":"Nat. Med."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125005884?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1742706125005884?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T14:18:54Z","timestamp":1772893134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1742706125005884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":52,"alternative-id":["S1742706125005884"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2025.08.005","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macroporous hydrogel-based mRNA cancer vaccine for in situ recruitment and modulation of dendritic cells","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2025.08.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Acta Materialia Inc. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}